cabozantinib
exelixis
['urothelial carcinoma', 'atlantis', 'blcsm', 'cabozantinib', 'urothelial', 'biomarker']
no benefit to maintenance cabozantinib after chemotherapy in advanced urothelial carcinoma (the biomarker-negative cohort) as reported by dr. robert jones "atlantis trial" #asco22 #blcsm
Medical oncologist - Developmental Therapeutics - NIH/NCI - opinions my own - retweet is not endorsement